重药控股(000950) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 reached ¥21,023,184,549.43, an increase of 5.57% year-on-year[5] - Net profit attributable to shareholders was ¥101,744,356.00, representing a significant increase of 87.94% compared to the same period last year[5] - Total operating revenue for Q3 2025 reached ¥62.21 billion, an increase of 4.5% compared to ¥59.69 billion in the same period last year[24] - Operating profit for the period was ¥665.17 million, up from ¥548.07 million, reflecting a growth of 21.4% year-over-year[25] - Net profit attributable to shareholders was ¥384.01 million, a 31.5% increase from ¥292.23 million in the previous year[25] - The comprehensive income totalled ¥524.90 million, compared to ¥406.57 million in the previous year, marking an increase of 29.1%[25] - Basic and diluted earnings per share increased to 0.22 from 0.17 year-over-year[26] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥67,712,459,177.41, reflecting a 1.62% increase from the end of the previous year[5] - Total assets amounted to ¥67.71 billion, compared to ¥66.63 billion at the end of the previous period, indicating a growth of 1.6%[23] - Total liabilities reached ¥51.24 billion, an increase of 2.1% from ¥50.17 billion in the previous year[23] - Short-term borrowings increased significantly to ¥18.50 billion, up from ¥15.38 billion, representing a rise of 20.5%[23] Cash Flow - The net cash flow from operating activities showed a net outflow of ¥2,330,265,161.40, which is a 26.03% reduction in outflow compared to the previous year[15] - Cash inflow from operating activities totaled ¥66,990,294,029.22, compared to ¥66,043,460,134.24 in the previous period[26] - Cash outflow from investing activities was ¥296,998,614.76, compared to ¥334,191,754.85 in the previous period[27] - Net cash flow from investing activities was -¥61,763,249.00, an improvement from -¥183,397,586.17 year-over-year[27] - Cash inflow from financing activities was ¥17,966,913,059.01, down from ¥19,960,387,270.76 in the previous period[27] - Net cash flow from financing activities was -¥668,375,594.80, compared to a positive flow of ¥1,059,068,645.83 in the previous period[27] - The ending balance of cash and cash equivalents decreased to ¥1,726,578,569.04 from ¥2,833,252,987.95 year-over-year[27] Shareholder Information - Total number of common shareholders at the end of the reporting period is 42,036[17] - The largest shareholder, Chongqing Pharmaceutical Health Industry Co., Ltd., holds 38.47% of shares, totaling 664,900,806 shares[17] - The second-largest shareholder, Chongqing Urban Construction Investment (Group) Co., Ltd., holds 16.33% of shares, totaling 282,294,397 shares[17] - The company has repurchased a total of 15,406,600 shares, accounting for approximately 0.8915% of the total share capital, with a total payment of 80,998,765.98 RMB[20] - The company’s repurchase account is included among the top 10 shareholders but is not listed due to regulatory guidelines[20] Investment and Expenses - The company reported a 42.13% decrease in investment income, totaling ¥139,991,780.84 compared to the previous year[13] - Research and development expenses were reported at ¥114.78 million, a decrease from ¥8.58 million in the previous year[24] - The company experienced a 61.97% increase in credit impairment losses, amounting to ¥572,285,350.10[14] - The company reported a credit impairment loss of ¥572.29 million, worsening from a loss of ¥353.32 million in the previous year[25] Cash and Inventory - Cash and cash equivalents at the end of the reporting period amount to 5,307,059,323.75 RMB, down from 9,391,508,185.09 RMB at the beginning of the period[21] - Accounts receivable increased to 37,985,587,830.15 RMB from 32,947,915,146.27 RMB, reflecting a growth of approximately 15.5%[21] - Inventory at the end of the reporting period is 10,163,510,004.65 RMB, compared to 9,977,409,800.46 RMB at the beginning, indicating an increase of about 1.9%[21] - Long-term equity investments increased to 3,356,673,294.76 RMB from 3,261,118,253.42 RMB, showing a growth of approximately 2.9%[21]